Bursting with Ride! The Oldest Hospital in Nevada Donates a Historic Heirloom to Recognize 160 Years of Healthcare and Emergency Medical Services in Northern Nevada
Recognized as one of the world’s leading breast cancer experts as a 2023 Legends in Cancer Honoree
Dr. Lee Schwartzberg, FACP, Section Chief of Medical Oncology at the William N. Pennington Cancer Institute at Renown, was honored as th
HealthyNV Project News
Study Shows Importance of Ensuring Participant and Provider Follow-up After a Genetic Screening Result
Released in partnership with the Desert Research Institute: New research from the Healthy Nevada Project® finds that a confirmed diagnosis does not always result in changes to patient care.
Presenting individuals with potentially life-al
Se Recomienda A Los Pacientes De Renown Que Los Acompane Una Persona De Apoyo A La Visita Medica O En La Estadia En El Hospital
Renown Health's public relations team supports media partners in finding experts on diverse health care topics. In addition, we provide information and answer all questions regarding Renown. We look forward to working with you.
Media On Campus
For patient confidentiality purposes, Renown Health policies require media to be escorted by the public relations staff at all times.
PR staff will gladly make parking arrangements, notify the appropriate hospital staff and help you find your destination.
Stand Ups/Live Broadcasts
Media may conduct stand ups and live broadcasts on our campuses. In the interest of patient confidentiality and traffic flow, a staff member will help you find the best location for your story.
We ask you to respect our obligation to protect our patients' well-being and legal right to privacy.
Patient Condition Inquiry
We follow regulations of the Health Insurance Portability and Accountability Act of 1996 (HIPAA) for all patients, including patients of public interest. HIPAA regulations specify which information may and may not be released without authorization from a patient.
Patient privacy regulations allow us to only share patient condition information about patients that appear in our directory.
Media inquiries require correct spelling of the patient's first and last name.
Definitions of "Condition" used by Renown Health
When describing a patient's condition, we can only release the following patient statuses:
Good - Vital signs such as pulse, temperature and blood pressure are stable and within normal limits. Patient is conscious, comfortable and there are no complications.
Fair - Vital signs are stable and within normal limits. Patient is conscious and alert although may be uncomfortable or in pain and may have minor complications.
Serious - Vital signs may be unstable or outside normal limits. The patient is acutely ill or injured and may have major complications.
Critical - Vital signs are unstable or outside normal limits. There are major complications.
Note: "Stable" is not a condition.
Beacon of Hope Shines on Our Community: Renown Welcomes First Baby of 2021
Renown Health is excited to announce a hopeful moment to start the new year with the first baby of 2021. Jessa Mae Estrada, 26, of Reno gave birth to baby Oli Amelia Estrada at 3:59 a.m. on Jan. 1, 2021. Baby Oli weighed 5 pounds, 14.4 ounces and was the first 2021 birth at any of the region’s hospitals. “Baby Oli’s birth serves as a beautiful symbol of hope for all of us as we look forward to brighter days ahead full of joy, promise and new beginnings,” said Tony Slonim, MD, DrPH, Renown’s President and CEO. “As we take time to reflect on the many challenges and uncertainties brought on in 2020, I will never forget the steadfast determination and resilience demonstrated by our entire community. For it is our collective ability to overcome adversity that makes celebratory moments like these even more meaningful.” Baby Oli is welcomed to the world by her father, Oliver Estrada, siblings Nate, 2, and Naz, 1, and grandparents Charito and Eduardo Estrada. “I am excited to welcome our first baby of 2021 and celebrate this joyful moment,” said Larry Duncan, Vice President of Pediatrics and Surgery and Administrator, Renown Children's Hospital. “I want to wish all of the new parents the best and make sure they know Renown is here to provide the quality care the families in our community deserve.” More than 4,000 babies are delivered each year at Renown Regional Medical Center. Renown Children’s Hospital has a Neonatal Intensive Care Unit (NICU), and the region’s only Children’s ER and Pediatric ICU, and is the only hospital affiliated with Children’s Miracle Network Hospitals (CMNH) in the region. Please see the above photo for you to share showing the healthy and happy, mom and baby. About Renown Health Renown Health is the region’s largest, locally owned and governed, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. With a diverse workforce of more than 7,000 employees, Renown has fostered a longstanding culture of excellence, determination and innovation. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the region’s largest, locally owned not-for-profit insurance company, Hometown Health. Renown’s institute model addresses social determinants of health a1nd includes: Child Health, Behavioral Health & Addiction, Healthy Aging and Health Innovation. Clinical institutes include: Cancer, Heart and Vascular Health, Neurosciences and Robotic Surgery. Renown is currently enrolling participants in the world’s largest community-based genetic population health study, the Healthy Nevada Project®. For more information visit, renown.org.
Read More About Beacon of Hope Shines on Our Community: Renown Welcomes First Baby of 2021
Gilead Sciences and Renown Institute for Health Innovation Announce Strategic Collaboration to Advance Understanding of Nonalcoholic Steatohepatitis (NASH)
Gilead Sciences, Inc. (Nasdaq: GILD) and the Renown Institute for Health Innovation (IHI) today announced a strategic collaboration to collect and analyze genetic and electronic health data that can enhance the understanding of nonalcoholic steatohepatitis (NASH) and potentially inform development of treatment options for the disease. Under the terms of the collaboration and license agreement, Gilead will provide funding to Renown IHI to sequence and analyze the DNA of 15,000 individuals living with NASH or nonalcoholic fatty liver disease (NAFLD) as well as a control cohort of 40,000 individuals in Nevada. “Combining the sequencing of protein coding DNA, with extensive electronic health record data will enable a deep analysis of the roles of genetics and environment in NASH incidence and progression,” said John McHutchison, AO, MD, Chief Scientific Officer and Head of Research and Development, Gilead Sciences. “The analysis of these large datasets in collaboration with Renown IHI could help identify genetic variants that impact the risk of developing NASH and thereby advance the discovery and development of new treatments for this disease.” Renown Health is Nevada’s most comprehensive and integrated healthcare network and maintains electronic health records for 1.02 million registered patients. In 2016, Renown Health and the Desert Research Institute established the Healthy Nevada Project (HNP), the nation’s first community-based population health study. In 2017 HNP began a partnership with Helix to leverage its population health services, Exome+™ sequencing, and consumer engagement tools. The HNP is now an ongoing collaboration between Renown IHI, the Desert Research Institute, a global leader in environmental data and applied research, and Helix, a personal genomics company. HNP combines genetic, environmental, social and clinical data to address individual and community health needs with the goal of improving health across the state and the nation. The HNP currently has 40,000 participants. “Combining genetic sequencing with large sets of data can play a critical role in understanding and identifying serious health risks, including diseases like NASH. We are excited to collaborate with Gilead to better understand the condition and its complexities,” said Anthony Slonim, MD., DrPH. “Any genetic variants identified in participants through the collaboration may be shared with the participants for patient care purposes.” About NASH Nonalcoholic steatohepatitis (NASH) is a chronic form of liver disease characterized by excess fat in the liver, inflammation, and liver cell damage. Inflammation and liver cell damage can cause scarring of the liver, or fibrosis, and ultimately lead to cirrhosis or liver cancer. NASH is more common in people with certain conditions, including obesity and type 2 diabetes. There are currently limited approved treatments for patients living with NASH. About Gilead Sciences Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com. About Renown Health Renown Health is a locally governed and locally owned, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. Renown is one of the region’s largest private employers with a workforce of more than 7,000. It comprises three acute care hospitals, a rehabilitation hospital, the area’s most comprehensive medical group and urgent care network, and the region’s largest and only locally owned not-for-profit insurance company, Hometown Health. Renown Health’s commitment has extended beyond traditional health care to include community health and well-being. Renown Health works to improve health care through science, research and genetics; forge community partnerships that improve lives and develop innovative models that are improving health care in Nevada. For more information, visit renown.org. About Helix Helix’s mission is to empower every person to improve their life through DNA. Helix is accelerating the integration of genomic data into clinical care and broadening the impact of large-scale population health programs by providing comprehensive expertise in DNA sequencing, bioinformatics, and individual engagement. Powered by their proprietary Exome+™ assay—a panel-grade exome enhanced by more than 300,000 informative non-coding regions—Helix offers health systems a scalable solution which enables the discovery of medically relevant, potentially life-saving, genetic information. Additionally, Helix offers a suite of DNA-powered products for continued individual engagement and discovery. Helix is headquartered in the San Francisco Bay Area and has one of the world’s largest CLIA-certified, CAP-accredited Next Generation Sequencing labs, located in San Diego, California. Learn more at www.helix.com. Helix, the Helix logo, and Exome+ are trademarks of Helix Opco, LLC. Gilead Forward-Looking Statement This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the risk that the parties may not realize the potential benefits of this collaboration, and Gilead may fail to discover, develop and commercialize any product candidates for the treatment of NASH. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000. Additional Media Contact: Sung Lee, Investors 650-524-7792 Arran Attridge, Media 650-425-8975
Read More About Gilead Sciences and Renown Institute for Health Innovation Announce Strategic Collaboration to Advance Understanding of Nonalcoholic Steatohepatitis (NASH)